Complete Support

Our dedicated and experienced field team is here to support your program from implementation, ongoing education and training through program assessment and review. 

Comprehensive Therapy Implementation

US map showing 200+ specialists. Baxter offers support from Portfolio managers, therapy development specialists that offer CRRT Acute therapies support, Clinical Educator, Field Technical Service
Over 200 highly-experienced specialists across the US work to help tailor your program to the needs of your facility

Clinical and Technical Support

Doctor on phone holding tablet

24/7 ICON (Intensive Care On-line Network) Clinical Support Help-line

  • Provides on-demand 24/7 clinical-focused support service via phone or email
  • Staffed by experienced clinical professionals, as well as on-call MDs and PharmDs
  • Simulates the situation in question and walks clinician through the process step-by-step
  • Supports 1,200 calls monthly from clinicians who are delivering CRRT
Diagram showing Baxter's support arms: 24/7 online support, in-house biomed support, and direct ordering and logistics support

24/7 Technical Support

In addition to your CRRT dedicated team of specialists, we also provide multiple support options. Get answers to your questions any time day or night.

  • 24/7 Online Support
  • In-house Biomed Support
  • Direct Ordering and Logistics Support
Nurse talking with Doctors and other healthcare professionals

Peer-to-peer Training and Education

At Baxter Critical Care Institute, we strive to increase confidence in therapy delivery throughout your hospital. By taking a versatile multi-channel approach to education, our programs are developed to help simplify processes while increasing consistency and safety. We customize training programs to align with the unique needs of your hospital, ICU, and staff. Global insights and knowledge-sharing ensure that our educational offerings are always state-of-the-art.

The PRISMAFLEX and PRISMAX Systems are intended for:
Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload.

Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where fluid removal of plasma components is indicated.

Rx Only. For safe and proper use of products mentioned herein refer to the appropriate Instructions for Use or Operator's Manual.

PHOXILLUM and PRISMASOL Renal Replacement Solution Indications and Important Risk Information

Indications and Usage 
PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.

Warnings and Precautions 
Electrolyte and Volume Abnormalities
PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately. PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis.

Blood Glucose Abnormalities
The use of PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.

Please see PHOXILLUM and PRISMASOL Solutions full Prescribing Information.

MARS is indicated for the treatment of drug overdose and poisonings. The only requirement is that the drug or chemical be dialyzable (in unbound form) and bound by charcoal and/or ion exchange resins.

MARS is not indicated for the treatment of chronic liver disease conditions or as a bridge to liver transplant. Safety and efficacy has not been demonstrated for those indications in controlled, randomized clinical trials. The effectiveness of the MARS device in patients that are sedated could not be established in clinical studies and therefore cannot be predicted in sedated patients.